Photo taken from Drew Moghanaki/X
Jan 28, 2024, 15:04
Drew Moghanaki: RECIST over-classified ‘progression’ in 81% of cases without progression.
Drew Moghanaki, Chief of Thoracic Oncology in the UCLA Department of Radiation Oncology, shared a post on X/Twitter:
“This study evaluating the accuracy of RECIST for LC monitoring after SBRT for stage I (85%) or metastatic (15%) NSCLC demonstrated a PPV of only 0.16.
RECIST over-classified ‘progression’ in 81% of cases without progression (47/58)”
Source: Drew Moghanaki/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:14
Nov 14, 2024, 16:29
Nov 14, 2024, 16:27
Nov 14, 2024, 16:22
Nov 14, 2024, 16:22
Nov 14, 2024, 16:13
Nov 14, 2024, 16:03